000118659 001__ 118659
000118659 005__ 20220921104421.0
000118659 0247_ $$2doi$$a10.3390/ph15060722
000118659 0248_ $$2sideral$$a129641
000118659 037__ $$aART-2022-129641
000118659 041__ $$aeng
000118659 100__ $$aNavarro Bielsa, A.$$uUniversidad de Zaragoza
000118659 245__ $$aCombination of photodynamic therapy and oral antifungals for the treatment of onychomycosis
000118659 260__ $$c2022
000118659 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118659 5203_ $$aOnychomycosis accounts for 50% of nail disorders, making it one of the most prevalent fungal diseases and a therapeutic challenge. Photodynamic therapy (PDT) could constitute a therapeutic alternative, owing to its good adherence, the low probability of resistance, the lack of interaction with antimicrobials, and its favorable adverse effect profile. This retrospective observational study included all patients with a microbiological diagnosis of onychomycosis treated with PDT at Miguel Servet University Hospital, Zaragoza (Spain), between January 2013 and June 2021. The protocol con-sisted of pre-treatment with 40% urea for 7 days, followed by 16% methyl-aminolevulinate (MAL) for 3 h and subsequent irradiation with a red-light LED lamp (37 J/cm2), every 1 or 2 weeks. Combined treatment with oral and/or topical antifungals was recorded. Of the 20 patients included (mean age, 59 ± 17 years), 55% were men. The most frequently detected microorganism was Trichophyton rubrum (55%). The most commonly affected location was the feet (90%): 50% of these cases were associated with tinea pedis. The median (standard deviation) number of PDT sessions was 6 (2.8). PDT was combined with systemic terbinafine (250 mg/day) in 10 cases (in 8 cases, this was administered for only 1 month), and with topical terbinafine in 3 cases. A complete clinical response was achieved in 80% (16) of cases and microbiological cure in 60% (12). PDT is a therapeutic alternative for ony-chomycosis, and can be administered either in monotherapy or combined with antifungals, allowing for a reduction in the duration and possible adverse effects of antifungal treatment and achieving higher cure rates than those obtained with either treatment alone.
000118659 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118659 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118659 700__ $$aGracia Cazaña, T.$$uUniversidad de Zaragoza
000118659 700__ $$aRobres, P.
000118659 700__ $$0(orcid)0000-0002-6227-861X$$aLópez, C.$$uUniversidad de Zaragoza
000118659 700__ $$aCalvo-Priego, M. D.
000118659 700__ $$aAspiroz, C.
000118659 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Y.$$uUniversidad de Zaragoza
000118659 7102_ $$15011$$2220$$aUniversidad de Zaragoza$$bDpto. CC.Agrar.y Medio Natural$$cÁrea Ecología
000118659 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000118659 773__ $$g15, 6 (2022), 722 [7 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000118659 8564_ $$s621114$$uhttps://zaguan.unizar.es/record/118659/files/texto_completo.pdf$$yVersión publicada
000118659 8564_ $$s2751960$$uhttps://zaguan.unizar.es/record/118659/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118659 909CO $$ooai:zaguan.unizar.es:118659$$particulos$$pdriver
000118659 951__ $$a2022-09-21-09:28:50
000118659 980__ $$aARTICLE